Combining gemcitabine and MSC delivering soluble TRAIL to target pancreatic adenocarcinoma and its stroma-Reference-Cited by-同舟云学术

Combining gemcitabine and MSC delivering soluble TRAIL to target pancreatic adenocarcinoma and its stroma

Published:2024-08 Issue:8 Volume:5 Page:101685
ISSN:2666-3791
Container-title:Cell Reports Medicine
language:en
Short-container-title:Cell Reports Medicine

Author:

Grisendi Giulia^ORCID,Dall’Ora Massimiliano,Casari Giulia,Spattini Giliola,Farshchian Moein,Melandri Aurora,Masciale Valentina,Lepore Fabio,Banchelli Federico,Costantini Riccardo Cuoghi,D’Esposito Angela,Chiavelli Chiara,Spano Carlotta,Spallanzani Andrea,Petrachi Tiziana,Veronesi Elena,Ferracin Manuela,Roncarati Roberta,Vinet Jonathan,Magistri Paolo,Catellani Barbara,Candini Olivia,Marra Caterina,Eccher Albino,Bonetti Luca Reggiani,Horwitz Edwin M.,Di Benedetto Fabrizio,Dominici Massimo

Publisher

Elsevier BV

Reference87 articles.

1. European cancer mortality predictions for the year 2014;Malvezzi;Ann. Oncol.,2014

2. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018;Ferlay;Eur. J. Cancer,2018

3. Pancreatic cancer;Kamisawa;Lancet (London, England),2016

4. TRAIL receptors are expressed in both malignant and stromal cells in pancreatic ductal adenocarcinoma;Dall'Ora;Am. J. Cancer Res.,2021

5. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial;Burris;J. Clin. Oncol.,1997

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HOXB6 and HOXB8 control immune-cancer cell interactions in pancreatic cancer;2024-09-06